JP7033549B2 - 細胞に基づくネオ抗原ワクチンおよびその使用 - Google Patents

細胞に基づくネオ抗原ワクチンおよびその使用 Download PDF

Info

Publication number
JP7033549B2
JP7033549B2 JP2018557312A JP2018557312A JP7033549B2 JP 7033549 B2 JP7033549 B2 JP 7033549B2 JP 2018557312 A JP2018557312 A JP 2018557312A JP 2018557312 A JP2018557312 A JP 2018557312A JP 7033549 B2 JP7033549 B2 JP 7033549B2
Authority
JP
Japan
Prior art keywords
cell
cells
cancer
neoantigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018557312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514393A (ja
JP2019514393A5 (https=
Inventor
スタンリー アール． リデル，
ジョシュア ヴィーチ，
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2019514393A publication Critical patent/JP2019514393A/ja
Publication of JP2019514393A5 publication Critical patent/JP2019514393A5/ja
Priority to JP2022029582A priority Critical patent/JP2022091750A/ja
Application granted granted Critical
Publication of JP7033549B2 publication Critical patent/JP7033549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018557312A 2016-05-04 2017-05-04 細胞に基づくネオ抗原ワクチンおよびその使用 Active JP7033549B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022029582A JP2022091750A (ja) 2016-05-04 2022-02-28 細胞に基づくネオ抗原ワクチンおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331906P 2016-05-04 2016-05-04
US62/331,906 2016-05-04
PCT/US2017/031171 WO2017192924A1 (en) 2016-05-04 2017-05-04 Cell-based neoantigen vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022029582A Division JP2022091750A (ja) 2016-05-04 2022-02-28 細胞に基づくネオ抗原ワクチンおよびその使用

Publications (3)

Publication Number Publication Date
JP2019514393A JP2019514393A (ja) 2019-06-06
JP2019514393A5 JP2019514393A5 (https=) 2020-06-11
JP7033549B2 true JP7033549B2 (ja) 2022-03-10

Family

ID=58739362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018557312A Active JP7033549B2 (ja) 2016-05-04 2017-05-04 細胞に基づくネオ抗原ワクチンおよびその使用
JP2022029582A Pending JP2022091750A (ja) 2016-05-04 2022-02-28 細胞に基づくネオ抗原ワクチンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022029582A Pending JP2022091750A (ja) 2016-05-04 2022-02-28 細胞に基づくネオ抗原ワクチンおよびその使用

Country Status (5)

Country Link
US (1) US11723962B2 (https=)
EP (1) EP3452082A1 (https=)
JP (2) JP7033549B2 (https=)
CA (1) CA3022267A1 (https=)
WO (1) WO2017192924A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
AU2017378482B2 (en) 2016-12-16 2024-06-13 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3060523A1 (en) 2017-04-18 2018-10-25 Yale University A platform for t lymphocyte genome engineering and in vivo high-throughput screening thereof
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
CN111801415A (zh) * 2017-11-06 2020-10-20 路德维格癌症研究院 扩增淋巴细胞的方法
EP3706770A4 (en) * 2017-11-07 2021-10-27 Nektar Therapeutics IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
WO2019147604A2 (en) * 2018-01-23 2019-08-01 Vanderbilt University Self-antigen specific t-cells as vacines for augmenting engraftment and stability of autologous transfer
WO2019173441A1 (en) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing populations of cells and retroviral reagents for adoptive cell immunotherapy
JP2021522188A (ja) * 2018-04-18 2021-08-30 イエール ユニバーシティ 内因性遺伝子活性化を用いる多重腫瘍ワクチン接種のための組成物および方法
CN112533617A (zh) * 2018-04-25 2021-03-19 卫理公会医院体系公司 癌症新抗原和其在癌症疫苗和基于tcr的癌症免疫疗法中的效用
EP3796930A4 (en) * 2018-05-23 2022-05-04 Gritstone bio, Inc. IMMUNE CHECKPOINT INHIBITOR KO-EXPRESSION VECTORS
US12528848B2 (en) * 2018-05-25 2026-01-20 The Wistar Institute Of Anatomy And Biology Tumor-specific neoantigens and methods of using the same
AU2019288669B2 (en) 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
MX2021001938A (es) 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.
KR20210102231A (ko) 2018-11-09 2021-08-19 프레드 헛친슨 켄서 리서치 센터 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
US12227551B2 (en) 2018-12-11 2025-02-18 Obsidian Therapeutics, Inc. Membrane bound IL12 compositions and methods for tunable regulation
CN113164578B (zh) * 2019-01-03 2024-04-30 南京传奇生物科技有限公司 表达鞭毛蛋白多肽的经修饰的免疫细胞
CN111454358A (zh) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 一种嵌合抗原受体及其应用
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP4025244A1 (en) * 2019-09-02 2022-07-13 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CN110804594B (zh) * 2019-11-21 2020-11-20 启辰生生物科技(珠海)有限公司 工程化抗原递呈细胞及其在用于活化cd3+免疫细胞中的应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
AU2021253641A1 (en) * 2020-04-07 2022-10-27 Evaxion Biotech A/S Neoepitope immunotherapy with APC targeting unit
GB202006254D0 (en) * 2020-04-28 2020-06-10 Institute Of Cancer Res Anti-cancer vaccines and related therapy
CN111690609B (zh) * 2020-06-30 2022-04-05 深圳裕泰抗原科技有限公司 一种新生抗原免疫原性的测试方法
WO2022023521A2 (en) * 2020-07-30 2022-02-03 Evaxion Biotech A/S Process for preparation of neopepitope-containing vaccine agents
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
WO2022067038A1 (en) * 2020-09-25 2022-03-31 President And Fellows Of Harvard College Immunotherapeutic virus for the treatment of cancer
AR124826A1 (es) * 2021-02-08 2023-05-10 Hutchinson Fred Cancer Res Sistema y métodos para vincular la señalización de cd40 a la unión del antígeno
CA3245584A1 (en) 2022-03-10 2023-09-14 City Of Hope IL-12 Bound to the Membrane for Cellular Immunotherapy
WO2024118634A2 (en) * 2022-11-28 2024-06-06 The Trustees Of The University Of Pennsylvania In vivo expansion of car t cells and delivery of car target antigen to tumors using mrna lipid nanoparticles
CN117338914B (zh) * 2023-10-27 2024-09-06 中山市珈钰生物医药有限公司 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用
US20250144143A1 (en) * 2023-11-06 2025-05-08 Immunitybio, Inc. Virally Educated T cells
WO2025185599A1 (zh) * 2024-03-04 2025-09-12 清华大学 编码膜型IL-12细胞因子佐剂的mRNA肿瘤疫苗及其用途
CN119823283B (zh) * 2025-01-08 2025-08-26 国科明耀(山东)医学科技有限公司 一种il-12-cd137嵌合蛋白、一种功能增强型工程化nk细胞、其制备及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
JP2008539751A (ja) 2005-05-10 2008-11-20 アヴァリス・アーベー 新規組成物およびその使用
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US20020155093A1 (en) 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
JP2006506072A (ja) * 2002-11-12 2006-02-23 デイッセロース，アルバート，ビー アデノウイルスベクターワクチン
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
US20090324630A1 (en) 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EP2697367B1 (en) 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
JP6117515B2 (ja) 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
BR112016021345A8 (pt) 2014-03-17 2022-07-05 Tapimmune Inc Composições de vacina de molécula de ácido nucleico e usos das mesmas
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
MX389823B (es) 2014-10-27 2025-03-20 Fred Hutchinson Cancer Center Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
WO2016069641A1 (en) 2014-10-28 2016-05-06 Thomas Jefferson University COMPOSITIONS AND METHODS OF USING TRANSFER RNAS (tRNAs)
AU2016261358B2 (en) 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
WO2017059186A1 (en) 2015-10-01 2017-04-06 QXMedical, LLC. Catheter structure with improved support and related systems, methods and devices
US20180311257A1 (en) 2015-11-03 2018-11-01 Hochschule Darmstadt Selective hdac8 inhibitors and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
JP2008539751A (ja) 2005-05-10 2008-11-20 アヴァリス・アーベー 新規組成物およびその使用
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADHAM S BEAR; CONRAD R CRUZ; AARON E FOSTER，T CELLS AS VEHICLES FOR CANCER VACCINATION，JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY，米国，2011年，VOL:2011，PAGE(S):1 - 7，http://dx.doi.org/10.1155/2011/417403
CARRENO BEATRIZ M; ET AL，CANCER IMMUNOTHERAPY. A DENDRITIC CELL VACCINE INCREASES THE BREADTH AND DIVERSITY 以下備考，SCIENCE，2015年05月15日，VOL:348, NR:6236，PAGE(S):803 - 808，http://dx.doi.org/10.1126/science.aaa3828，OF MELANOMA NEOANTIGEN-SPECIFIC T CELLS
J. Immunol., 1998, 160(3):1139-1147
Molecular Therapy, 2012, 20(5):927-937
SONG-NAN ZHANG; IL-KYU CHOI; JING-HUA HUANG; ET AL，OPTIMIZING DC VACCINATION BY COMBINATION WITH ONCOLYTIC ADENOVIRUS COEXPRESSING IL-12 AND GM-CSF，MOLECULAR THERAPY，2011年08月，VOL:19, NR:8，PAGE(S):1558 - 1568，http://dx.doi.org/10.1038/mt.2011.29
YOZO NAKAZAWA; LESLIE E HUYE; GIANPIETRO DOTTI; ET AL，OPTIMIZATION OF THE PIGGYBAC TRANSPOSON SYSTEM FOR THE SUSTAINED GENETIC MODIFICATION 以下備考，J.IMMUNOTHER.，2009年10月，VOL:32 ,NR:8，PAGE(S):1-18，http://dx.doi.org/10.1097/CJI.0b013e3181ad762b，OF HUMAN T LYMPHOCYTES

Also Published As

Publication number Publication date
CA3022267A1 (en) 2017-11-09
JP2022091750A (ja) 2022-06-21
US20190224236A1 (en) 2019-07-25
JP2019514393A (ja) 2019-06-06
EP3452082A1 (en) 2019-03-13
US11723962B2 (en) 2023-08-15
WO2017192924A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
JP7033549B2 (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US20240083968A1 (en) Treatment of cancer using chimeric cd3 receptor proteins
TWI787599B (zh) 嵌合抗原和ｔ細胞受體及使用方法
JP2023109921A (ja) 改変された多能性幹細胞並びに製造方法及び使用方法
US20200360431A1 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US20230074800A1 (en) Car-t cell therapies with enhanced efficacy
US20190375815A1 (en) Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US20200061113A1 (en) Chimeric antigen receptor therapy characterization assays and uses thereof
JP2021500894A (ja) キメラ抗原受容体発現細胞を作製する方法
JP2023515211A (ja) キメラ抗原受容体発現細胞を作製する方法
JP2021509009A (ja) Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
JP2018519842A (ja) 免疫細胞の有効性および増大を改善する方法
JP2018516592A (ja) キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
KR20140127816A (ko) 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
AU2021326504B2 (en) Improving immune cell function
JP7690597B2 (ja) 免疫細胞機能の改善
WO2018111340A1 (en) Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220228

R150 Certificate of patent or registration of utility model

Ref document number: 7033549

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250